|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT00000146 |
|
Date of registration:
|
23/09/1999 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Optic Neuritis Treatment Trial (ONTT)
|
|
Scientific title:
|
|
|
Date of first enrolment:
|
July 1988 |
|
Target sample size:
|
|
|
Recruitment status: |
Active, not recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT00000146 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Masking: Single Blind, Primary Purpose: Treatment
|
|
Phase:
|
Phase 3
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Key inclusion & exclusion criteria
|
The major eligibility criteria for enrollment into the ONTT included the following:
Age range of 18 to 46 years
Acute unilateral optic neuritis with visual symptoms for 8 days or less
A relative afferent pupillary defect and a visual field defect in the affected eye
No previous episodes of optic neuritis in the affected eye
No previous corticosteroid treatment for optic neuritis or multiple sclerosis
No systemic disease other than multiple sclerosis that might be the cause of the optic
neuritis
Age minimum:
18 Years
Age maximum:
46 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Multiple Sclerosis
|
|
Optic Neuritis
|
|
Intervention(s)
|
|
Drug: Methylprednisolone
|
|
Drug: Prednisone
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|